CN104557955A - 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途 - Google Patents

作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途 Download PDF

Info

Publication number
CN104557955A
CN104557955A CN201310504853.4A CN201310504853A CN104557955A CN 104557955 A CN104557955 A CN 104557955A CN 201310504853 A CN201310504853 A CN 201310504853A CN 104557955 A CN104557955 A CN 104557955A
Authority
CN
China
Prior art keywords
compound
cancer
pi3k
general formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201310504853.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104557955B (zh
Inventor
程建军
秦继红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Huilun Pharmaceutical Co ltd
Original Assignee
SHANGHAI HUILUN TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI HUILUN TECHNOLOGY Co Ltd filed Critical SHANGHAI HUILUN TECHNOLOGY Co Ltd
Priority to CN201310504853.4A priority Critical patent/CN104557955B/zh
Publication of CN104557955A publication Critical patent/CN104557955A/zh
Application granted granted Critical
Publication of CN104557955B publication Critical patent/CN104557955B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
CN201310504853.4A 2013-10-23 2013-10-23 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途 Active CN104557955B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310504853.4A CN104557955B (zh) 2013-10-23 2013-10-23 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310504853.4A CN104557955B (zh) 2013-10-23 2013-10-23 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途

Publications (2)

Publication Number Publication Date
CN104557955A true CN104557955A (zh) 2015-04-29
CN104557955B CN104557955B (zh) 2017-05-03

Family

ID=53075118

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310504853.4A Active CN104557955B (zh) 2013-10-23 2013-10-23 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途

Country Status (1)

Country Link
CN (1) CN104557955B (und)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2121031A1 (en) * 1971-04-29 1972-11-02 Dr. Karl Thomae Gmbh, 7950 Biberach Base-substd quinazolines - thrombocyte aggregation inhibitors
WO1999043674A1 (fr) * 1998-02-27 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Remedes contre les dysfonctionnements de l'erection
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
CN101754759A (zh) * 2007-05-18 2010-06-23 史密丝克莱恩比彻姆公司 用作pi3激酶抑制剂的喹啉衍生物
CN102020657A (zh) * 2009-09-11 2011-04-20 上海艾力斯医药科技有限公司 稠合杂芳基衍生物、制备方法及其应用
CN102498115A (zh) * 2009-08-20 2012-06-13 卡鲁斯治疗有限公司 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物
CN103313989A (zh) * 2010-12-16 2013-09-18 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2121031A1 (en) * 1971-04-29 1972-11-02 Dr. Karl Thomae Gmbh, 7950 Biberach Base-substd quinazolines - thrombocyte aggregation inhibitors
WO1999043674A1 (fr) * 1998-02-27 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Remedes contre les dysfonctionnements de l'erection
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
CN101754759A (zh) * 2007-05-18 2010-06-23 史密丝克莱恩比彻姆公司 用作pi3激酶抑制剂的喹啉衍生物
CN102498115A (zh) * 2009-08-20 2012-06-13 卡鲁斯治疗有限公司 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物
CN102020657A (zh) * 2009-09-11 2011-04-20 上海艾力斯医药科技有限公司 稠合杂芳基衍生物、制备方法及其应用
CN103313989A (zh) * 2010-12-16 2013-09-18 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法

Also Published As

Publication number Publication date
CN104557955B (zh) 2017-05-03

Similar Documents

Publication Publication Date Title
CN102816175B (zh) 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
US10793543B2 (en) Selective C-KIT kinase inhibitor
ES2868748T3 (es) Compuesto de piridina
CN105188704B (zh) 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法
CN109415360A (zh) 用于抑制shp2活性的化合物和组合物
CN107849022A (zh) 取代的喹唑啉化合物和其使用方法
CN106573906A (zh) 哌啶‑二酮衍生物
CN102295635B (zh) 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
CN104557871A (zh) 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途
CN105377835A (zh) 酪氨酸蛋白激酶调节剂及其应用方法
ES2762641T3 (es) Inhibidores de proteína quinasa de 2-aminopiridina sustituida con piridina
CN104926788A (zh) 取代哌啶类衍生物、含其的药物组合物及其在抗肿瘤中的应用
CN109851638A (zh) 取代的二氨基嘧啶化合物
CN104230952A (zh) 含有嘧啶骨架的化合物及其制备方法和用途
EP2685980A1 (en) Methods and use of bifunctional enzyme-building clamp-shaped molecules
CN103936762B (zh) 吗啉并喹啉类化合物，其制备方法和用途
CN104557913A (zh) 吡啶并嘧啶类化合物，其制备方法和用途
CN101314584A (zh) HGF/c-Met信号通道抑制剂及其制备方法和用途
CN104418867A (zh) 作为PI3K/mTOR抑制剂的化合物,其制备方法和用途
CA3130471C (en) Pan-raf kinase inhibitor and use thereof
CN103965175A (zh) 4-(取代苯氨基)喹唑啉类化合物、其制备方法及应用
CN114605391A (zh) 喹喔啉类衍生物及其制备方法和应用
CN103509024B (zh) 嘧啶并苯并氮杂卓类化合物及其作为抗肿瘤药物的应用
CN103429586A (zh) 哌嗪二酮化合物
CN104557955A (zh) 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20190429

Address after: Room 304-12, 665 Zhangjiang Road, Shanghai Free Trade Pilot Area, 201210

Patentee after: Shanghai Huilun Pharmaceutical Technology Co.,Ltd.

Address before: Room 650-10, Building No. 2, 351 Guoshoujing Road, Zhangjiang High-tech Park, Pudong New Area, Shanghai, 201203

Patentee before: SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190816

Address after: Room 650-10, Building No. 2, 351 Guoshoujing Road, Shanghai Free Trade Pilot Area, 201203

Patentee after: SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY Co.,Ltd.

Address before: Room 304-12, 665 Zhangjiang Road, Shanghai Free Trade Pilot Area, 201210

Patentee before: Shanghai Huilun Pharmaceutical Technology Co.,Ltd.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Room 650-10, Building No. 2, 351 Guoshoujing Road, Shanghai Free Trade Pilot Area, 201203

Patentee after: Shanghai Hui Bio Technology Co.,Ltd.

Address before: Room 650-10, Building No. 2, 351 Guoshoujing Road, Shanghai Free Trade Pilot Area, 201203

Patentee before: SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY Co.,Ltd.

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 200241 floor 10, building 5, No. 525, Yuanjiang Road, Minhang District, Shanghai

Patentee after: Shanghai Huilun Pharmaceutical Co.,Ltd.

Address before: Room 650-10, building 2, 351 GuoShouJing Road, Shanghai pilot Free Trade Zone, 201203

Patentee before: Shanghai Hui Bio Technology Co.,Ltd.